RecruitingNot ApplicableNCT06896994

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

Intravenous Infusion of Esketamine in Combination With Pregabalin and Duloxetine for Postherpetic Neuralgia

Sponsor

Beijing Tiantan Hospital

Enrollment

150 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Conditions

Postherpetic Neuralgia

Summary

To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called control group and a drug called esketamine group for people with postherpetic neuralgia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGesketamine group

In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.

DRUGcontrol group

receiving the combination of pregabalin and duloxetine